Miami, Florida – (NewMediaWire) – November 3, 2021 – Blue
Water Ventures International, (OTC: BWVI), has signed a non-binding letter of
intent which contemplates a proposed acquisition of Psycheceutical, Inc.
Following the closing of the anticipated acquisition, Psycheceutical would
emerge as the surviving company with a name and symbol change to follow.
“The closing of this
acquisition marks a pivotal event that will provide Psycheceutical with the
opportunity to achieve its next level of corporate growth as we advance our
promising psychedelic drug delivery technologies,” said Chad Harman,
Completion of the transaction
is subject to due diligence investigations by the relevant parties, the
negotiation and execution of a definitive share exchange agreement,
satisfaction of the conditions negotiated therein including the approval of the
Company’s Board of Directors, and the satisfaction of other customary closing
conditions. There can be no assurance that a definitive agreement will be
entered into or that the proposed transaction will be consummated. Further,
readers are cautioned that those portions of the LOI that describe the proposed
transaction, including the consideration to be issued therein, are non-binding.
About Psycheceutical, Inc.
Psycheceutical, Inc. is using cutting-edge delivery technologies to develop
safe and effective psychedelic pharmaceutical medicines. Powered by a team with
more than 100 years’ combined experience in development, regulatory approval
processes, and commercialization across the pharmaceutical industry.
Psycheceutical is on a mission to bring safety and efficacy to psychedelic
compounds. Learn more at Psycheceutical.com.
This press release contains forward-looking statements. Statements in this
press release that are not purely historical are forward-looking statements.
Such forward-looking statements include, among other things, references to
business and development plans. Actual results could differ from those
projected in any forward-looking statements due to numerous factors. These
forward-looking statements are made as of the date of this press release,
and Blue Water Ventures International assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information set forth
herein and should also refer to the risk factor disclosure set forth in the
reports and other documents filed with available at www.otcmarkets.com.
BWVI Investor Relations
Roger Tichenor, CEO
Psycheceutical, Inc. Investor
Michael Hlavsa, CFO
Kaia Roman, VP, Strategy &